Class information for:
Level 1: CTLA 4//IPILIMUMAB//CYTOTOXIC T LYMPHOCYTE ANTIGEN 4

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
6333 1432 41.4 91%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
353 16852 FOXP3//CTLA 4//REGULATORY T CELLS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CTLA 4 Author keyword 161 43% 20% 284
2 IPILIMUMAB Author keyword 103 48% 11% 158
3 CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 Author keyword 61 62% 4% 64
4 CTLA4 Author keyword 46 39% 6% 92
5 TREMELIMUMAB Author keyword 40 72% 2% 31
6 CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 Author keyword 24 59% 2% 27
7 LUDWIG CANC IMMUNOTHER Y Address 21 41% 3% 41
8 IMMUNE RELATED ADVERSE EVENTS Author keyword 20 100% 1% 9
9 CTLA 4 GENE Author keyword 12 56% 1% 15
10 ANTI PD L1 Author keyword 9 83% 0% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CTLA 4 161 43% 20% 284 Search CTLA+4 Search CTLA+4
2 IPILIMUMAB 103 48% 11% 158 Search IPILIMUMAB Search IPILIMUMAB
3 CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 61 62% 4% 64 Search CYTOTOXIC+T+LYMPHOCYTE+ANTIGEN+4 Search CYTOTOXIC+T+LYMPHOCYTE+ANTIGEN+4
4 CTLA4 46 39% 6% 92 Search CTLA4 Search CTLA4
5 TREMELIMUMAB 40 72% 2% 31 Search TREMELIMUMAB Search TREMELIMUMAB
6 CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 24 59% 2% 27 Search CYTOTOXIC+T+LYMPHOCYTE+ASSOCIATED+ANTIGEN+4 Search CYTOTOXIC+T+LYMPHOCYTE+ASSOCIATED+ANTIGEN+4
7 IMMUNE RELATED ADVERSE EVENTS 20 100% 1% 9 Search IMMUNE+RELATED+ADVERSE+EVENTS Search IMMUNE+RELATED+ADVERSE+EVENTS
8 CTLA 4 GENE 12 56% 1% 15 Search CTLA+4+GENE Search CTLA+4+GENE
9 ANTI PD L1 9 83% 0% 5 Search ANTI+PD+L1 Search ANTI+PD+L1
10 MDX 010 9 83% 0% 5 Search MDX+010 Search MDX+010

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CTLA 4 BLOCKADE 88 43% 11% 156
2 CTLA 4 DEFICIENT MICE 62 73% 3% 47
3 LYMPHOCYTE ASSOCIATED ANTIGEN 4 61 36% 10% 137
4 MULTIORGAN TISSUE DESTRUCTION 49 64% 3% 48
5 EXON 1 POLYMORPHISMS 47 88% 2% 22
6 T LYMPHOCYTE ANTIGEN 4 43 48% 5% 66
7 CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 41 100% 1% 15
8 ANTI CTLA 4 ANTIBODY 39 73% 2% 30
9 PRETREATED ADVANCED MELANOMA 38 89% 1% 17
10 CLATHRIN ASSOCIATED PROTEIN 37 64% 3% 36

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Immune Checkpoint Blockade in Cancer Therapy 2015 12 82 54%
Confusing signals: Recent progress in CTLA-4 biology 2015 9 94 62%
Immune Modulation in Cancer with Antibodies 2014 49 72 51%
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events 2007 126 12 100%
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience 2015 4 104 45%
CTLA-4: new insights into its biological function and use in tumor immunotherapy 2002 404 85 64%
Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma 2015 2 45 78%
CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy 2001 430 128 58%
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy 2006 192 49 69%
A molecular perspective of CTLA-4 function 2006 219 188 62%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 LUDWIG CANC IMMUNOTHER Y 21 41% 2.9% 41
2 CELL SIGNALLING SECT 7 48% 0.8% 11
3 DERMOPATH 6 100% 0.3% 4
4 MED ONCOL IMMUNOTHER Y 5 24% 1.2% 17
5 CANC IMMUNOTHER Y INNOVAT THER Y UNIT 4 67% 0.3% 4
6 HEMATOL NEOPLAST DIS BONE MARROW TRANSPLAN 4 56% 0.3% 5
7 DERMATOLCICU976 3 100% 0.2% 3
8 TRANSLAT A 3 100% 0.2% 3
9 SHANGHAI ORTHOPAED TRAUMATOL 3 45% 0.3% 5
10 DONALD A ADAM COMPREHENS MELANOMA 3 35% 0.5% 7

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000231261 CD28//CD80//B7
2 0.0000199123 B7 H4//PD 1//PD L1
3 0.0000158914 ICOS//B7RP 1//ICOSL
4 0.0000158395 AUTOIMMUNE THYROID DISEASE//HASHIMOTOS THYROIDITIS//AUTOIMMUNE THYROIDITIS
5 0.0000096653 RECOMBINANT VACCINE GRP//ABSCOPAL EFFECT//IMMUNOGENIC TUMOR CELL DEATH
6 0.0000087694 BELAGENPUMATUCEL L//SRL172//PA MSHA
7 0.0000083218 BIOCHEMOTHERAPY//METASTATIC MELANOMA//DACARBAZINE
8 0.0000066209 SECRETION INHIBITION//RNF13//PROTEASE ASSOCIATED DOMAIN
9 0.0000065464 FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL
10 0.0000061215 VEMURAFENIB//B RAF//BRAF INHIBITOR